November 2, 2026: HHS tells compounders it will not enforce peptide regulations
Source · Partnership for Safe Medicines
TLDR
Partnership for Safe Medicines reports that HHS announced enforcement discretion for six unapproved peptides, meaning it would not take legal action against pharmacies compounding them. The report says an FDA advisory committee recommended their eligibility for compounding despite FDA scientists’ concerns about insufficient safety and efficacy evidence; state restrictions may still apply.
- 01The six peptides are BPC-157, epitalon, KPV, MOTS-c, semax, and TB,500, as named in the article.
- 02PSM criticized the evidence supporting these products and alleged conflicts-of-interest violations in the advisory committee’s composition.
- 03According to Politico’s coverage cited in the article, state pharmacy boards may maintain prohibitions despite federal enforcement discretion.
Why it matters Editorial
The reported policy changes federal enforcement toward six unapproved peptides without resolving the cited evidence gaps or overriding state restrictions.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
Caribbean National Weekly